Mesoblast (ASX:MSB) share price tumbles 8% giving back most of yesterday's gains

What's happened to the company's shares?

| More on:
a doctor with stethoscope around neck sits as a computer with head in hand, looking despondent.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Ltd (ASX: MSB) share price was in reverse today after surging more than 11% on Monday. The allogeneic cellular medicines company announced a trial update to its rexlemestrocel-L drug.

At the closing bell, Mesoblast shares finished the day down 8.68% to $1.735.

Why are Mesoblast shares falling?

Investors appeared to be taking profit off the table, sending the Mesoblast share price lower.

Following yesterday's astronomical gains, trading volumes rocketed to levels not seen since early September.

The company provided results from its phase 3 trial of rexlemestrocel-l in 565 patients suffering from chronic heart failure.

Presented at the American Heart Association (AHA) annual Scientific Sessions, Mesoblast highlighted a key takeaway from the landmark study. This related to the significant relationship between the presence of systemic inflammation and the treatment benefit with rexlemestrocel-L.

In particular, a single dose of rexlemestrocel-L, along with standard of care, reduced the incidence of heart attacks or strokes by 65% across all patients. This figure is compared against standard of care alone.

In addition, the same dosage of rexlemestrocel-L with standard of care diminished the incidence of cardiovascular death, heart attacks, or strokes by 33%.

How does rexlemestrocel-L work?

Rexlemestrocel-L reduces inflammatory cytokine production by immune cells, generating improved local networks of blood vessels within the damaged heart. In turn, this lowers the risk of plaque rupture in major arteries.

Heart failure affects around 6.5 million people in the United States and 26 million people globally, with rates increasing every year. The mortality rate approaches 50% at 5 years as patients progress beyond New York Heart Association (NYHA) class II disease.

Mesoblast share price summary

In the past 12 months, Mesoblast shares have disappointed investor expectations, failing to take off. The company's share price is down by almost 50% since this time last year, and down almost 23% year-to-date.

It's worth noting that Mesoblast shares are a long way off their 52-week high of $5.05.

Based on today's price, Mesoblast presides a market capitalisation of around $1.13 billion, with approximately 648.7 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »